Evidence map›Paper›PMID 18955324›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2010

Effects of Satureja khuzestanica on Serum Glucose, Lipids and Markers of Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Double-Blind Randomized Controlled Trial.

Sanaz Vosough-Ghanbari, Roja Rahimi, Shabnam Kharabaf, Shima Zeinali, Azadeh Mohammadirad, Somayeh Amini, Nargues Yasa, Alinazar Salehnia, Tayebeh Toliat, Shekoufeh Nikfar and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Trial
  2. Current Knowledge of the GenusPharmaceuticals (Basel, Switzerland) · 2026
    Review
  3. Review
  4. A comprehensive review of summer savory (Frontiers in pharmacology · 2023
    Review
  5. Review
  6. Natural Compounds ofPharmaceuticals (Basel, Switzerland) · 2022
    Article
  7. Review
  8. Review
  9. Research in pharmaceutical sciences · 2020
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. In vitro scolicidal effect of Satureja khuzistanica (Jamzad) essential oil.Asian Pacific journal of tropical biomedicine · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sanaz Vosough-GhanbariFaculty of Pharmacy and Pharmaceutical Sciences Research Center (PSRC), Endocrinology and Metabolism Research Center (EMRC) and Faculty of Medicine, Medicinal Plants Research Center (MPRC), Tehran University of Medical Sciences (TUMS) and Drug Selecting Committee, Food and Drug Organization, and Food and Drug Laboratory Research Center, Tehran, Iran.
Roja Rahimi
Shabnam Kharabaf
Shima Zeinali
Azadeh Mohammadirad
Somayeh Amini
Nargues Yasa
Alinazar Salehnia
Tayebeh Toliat
Shekoufeh Nikfar
Bagher Larijani
Mohammad Abdollahi

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Satureja khuzestanica is an endemic plant of Iran that is widely distributed in the Southern part of the country. It has antioxidant properties and thus it seems to be useful in diseases related to oxidative stress such as diabetes and hyperlipidemia. The present study investigates the effect of S. khuzestanica supplement in metabolic parameters of hyperlipidemic patients with type 2 diabetes mellitus. Twenty-one hyperlipidemic patients with type 2 diabetes mellitus were randomized in a double blind, placebo controlled clinical trial to receive either S. khuzestanica (tablets contain 250 mg dried leaves) or placebo once a day for 60 days. Blood samples were obtained at baseline and at the end of the study. Samples were analyzed for levels of glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride, creatinine, thiobarbituric acid reactive substances (TBARS) as marker of lipid peroxidation and ferric reducing ability (total antioxidant power, TAP). Treatment of patients by S. khuzestanica for 60 days induced significant decrease in total cholesterol (P = 0.008) and LDL-cholesterol (P = 0.03) while increased HDL-cholesterol (P = 0.02) and TAP (P = 0.007) in comparison with the baseline values. S. khuzestanica did not alter blood glucose, triglyceride, creatinin and TBARS levels. In comparison with baseline values, no significant change was observed in blood glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride, creatinine, TBARS and TAP in placebo-treated group. Usage of S. khuzestanica as a supplement to drug regimen of diabetic type 2 patients with hyperlipidemia is recommended.

Identifiers

PMID18955324
PMCPMC2892343

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.